SCIMED ANNOUNCES MOTION FILED
SCIMED ANNOUNCES MOTION FILED MINNEAPOLIS, Oct. 7 /PRNewswire/ -- SCIMED Life Systems, Inc.
(NASDAQ: SMLS) announced today that Schneider (U.S.A.), Inc. and Schneider (Europe) A.G., subsidiaries of Pfizer, Inc., have filed a motion to amend and supplement their complaint against SCIMED for the sale of the EXPRESS(R) rapid exchange catheter, to include SCIMED's next-generation rapid exchange catheter, which is currently under FDA review.
As previously reported, these Pfizer subsidiaries filed a lawsuit in April 1991 alleging that the EXPRESS infringes U.S. Patent No. 4,762,129. The company is in discovery relating to this litigation, and parties are to be ready for trial in early 1993, although no trial date has been set. Dale A. Spencer, president and chief executive officer, commented, "Naturally, since SCIMED's patent counsel is handling this litigation, we cannot comment on the specifics of this motion. We can say that we remain committed to defending our position in the rapid exchange segment of the coronary angioplasty catheter market, which is why one of our highest priorities continues to be to develop multiple product concepts to address that market's needs." SCIMED Life Systems, Inc. develops, manufactures and markets disposable medical devices, principally coronary angioplasty catheters, for non-surgical treatment of cardiovascular disease. SCIMED's shares are traded on the NASDAQ National Market System under the symbol SMLS. -0- 10/7/92 /CONTACT: Karen J. Kelsey of SCIMED, 612-494-1329/ (SMLS) CO: SCIMED Life Systems, Inc. ST: Minnesota IN: MTC SU:
KH -- MN099 -- 7348 10/07/92 09:18 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 7, 1992|
|Previous Article:||HERCULES SAYS LANGUAGE IN THE DEPARTMENT OF DEFENSE APPROPRIATIONS BILL FOR 1993 REGARDING TITAN IV SRMU PROGRAM IS A POSITIVE STEP|
|Next Article:||SONOCO REPORTS THIRD QUARTER RESULTS|